Pfizer India
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Pfizer India's recent strategic initiatives, including the successful launch of high-demand products like Prevenar-20 and Emblaveo, have positioned the company for moderate revenue growth despite a backdrop of slowing overall growth in the sector. Management's focus on operational efficiency, exemplified by a significant reduction in employee count and a partnership with Cipla to enhance distribution, is expected to support stable margins and improve market penetration, particularly in non-metro areas. While the company faces challenges such as regulatory pressures and product concentration risks, its strong cash position and commitment to high-margin, specialized therapies provide a solid foundation for future growth. Vista's financial outlook reflects these dynamics, projecting stable margins and a fair valuation, with a target price indicating limited upside. Over the next 12-24 months, Pfizer India is well-positioned to capitalize on its strategic initiatives, although it must navigate potential headwinds from pricing regulations and market competition
Why We Like This Stock
- Successful launches of high-demand products like Prevenar-20 and Emblaveo are expected to drive revenue growth
- Strategic partnership with Cipla enhances distribution capabilities, particularly in non-metro markets
- Strong cash position allows for flexibility in capital allocation, supporting potential dividends or M&A
Things To Watch Out For
- Regulatory pressures related to NLEM pricing could impact profitability and product availability
- Product concentration risks remain a concern, potentially affecting revenue stability
- Moderating overall revenue growth in the sector may limit Pfizer's market share expansion
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,193 | 2,281 | 2,520 | 2,555 | 2,743 |
| Profit Before Tax (Cr.) | 741 | 845 | 1,025 | 1,094 | 1,168 |
| PBT Margin | 33.8% | 37.0% | 4067.5% | 42.8% | 42.6% |
| Net Profit (Cr.) | 583 | 625 | 754 | 805 | 859 |
| Earnings Per Share | 127.4 | 136.7 | 164.7 | 175.9 | 187.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 6,000 | 29-Jul-2026 |
Company Overview
Show Company Profile
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.